A real-world analysis published in Kidney Research and Clinical Practice reports that patients with chronic kidney disease who started a sodium-glucose cotransporter 2 inhibitor alongside a glucagon-like peptide-1 receptor agonist had lower risks of major adverse kidney events and death than patients who started the SGLT2 inhibitor alone. The cardiovascular endpoint did not move.

The two drug classes involved are SGLT2 inhibitors, which push glucose out through the urine and are already standard kidney protection, and GLP-1 receptor agonists, the peptide-based class that includes semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). Each has its own kidney evidence base, and the open question has been what happens when a patient is on both.

Two classes, one combined question

The researchers pulled electronic health records from TriNetX and compared patients initiating combined therapy against those initiating SGLT2 inhibitor monotherapy, with 1:1 propensity score matching. Patients had to stay on their assigned strategy for the first six months, with outcome follow-up running from month six to two years after treatment started.

That design detail matters more than it looks. By starting the clock six months late, the authors exclude the early dropouts and the people who switched, which is a reasonable way to compare strategies and also a way to compare unusually adherent populations.

Key results

Among 178,930 patients, just 1,154 (0.65%) initiated combined therapy, against 24,134 (13.49%) on SGLT2 inhibitor alone, leaving 1,150 per group after matching. Combined therapy was associated with a lower risk of major adverse kidney events (adjusted hazard ratio 0.62; 95% CI 0.48 to 0.80) and of all-cause mortality (aHR 0.58; 95% CI 0.40 to 0.83), both at p below 0.01.

The cardiovascular endpoint came back flat, at an adjusted hazard ratio of 0.88 (95% CI 0.70 to 1.11; p = 0.29). A mortality signal without a matching cardiovascular signal is the kind of result that invites a second look rather than settling anything.

Limitations

This is an observational analysis of electronic health records, not a randomized trial, and propensity matching cannot remove confounding it cannot see. Fewer than one percent of the cohort was on combined therapy, which makes that group unusual by definition, and the authors conclude that further studies are needed to clarify the kidney and mortality effects.

Why a randomized trial is the next step

The association reported here is large, consistent across two of three endpoints, and drawn from a database big enough to find a rare treatment pattern at all. What it is not is proof that adding the second drug caused the difference, and the authors do not claim otherwise.